摘要
目的 探讨糖类抗原CA199、CA242及CEA联合检测对胰腺癌患者的临床诊断价值.方法 检测46例胰腺癌患者以及66例健康体检者外周血清中肿瘤标志物的水平,并对结果进行分析.结果 胰腺癌患者血清CA199、CA242及CEA值均明显高于正常组,两者比较有显著性差异(P〈0.05);CA199、CA242及CEA联合检测较单测任何一项其灵敏度、特异度均有提高,分别达到86.3%和90.6%.结论 胰腺癌肿瘤标志物CA199、CA242及CEA可作为早期诊断胰腺癌的工具,联检CA199、CA242及CEA能提高对胰腺癌的诊断和鉴别诊断效率.
Objective To investigate the clinical value of combined test of serum CA199, CA242 and CEA levels in the diagnosis of patients with pancreatic cancer. Methods Detection of serum tumor markers CA199, CA242, and CEA was carried out in 46 patients with pancreatic carcinoma and 66 healthy volunteers. Results Serum CA199, CA242 and CEA levels in pancreatic cancer patients were significeantly higher than those in normal eontrols and benign pancreatic lesion patients (P 〈 0.05). If serum CA199, CA242 and CEA were detected simultaneously, the sensitivity and speeificity of diagnosis of pancreatic cancer could be improved, and reached 86.3% and 90.6% respectively. Conclusion The changes of serum CA199, CA.242 and CEA levels are helpful in diagnosis of pancreatic cancer. The combined detection of serum CA199, CA242 and CEA could improve the sensitivity, and specificity in diagonosis and differential diagnosis of panereatie cancer.
出处
《医学检验与临床》
2010年第5期14-15,13,共3页
Medical Laboratory Science and Clinics